Immuno-PET imaging based radioimmunotherapy in head and neck squamous cell carcinoma model

The epidermal growth factor receptor (EGFR) is one of the most comprehensively studied molecular targets in head and neck squamous cell carcinoma (HNSCC). However, inherent and acquired resistance are serious problems and are responsible for limited clinical efficacy and tumor recurrence. In this study, we evaluated the feasibility of immuno-positron emission tomography (PET) imaging and radioimmunotherapy (RIT) with 64Cu-/177Lu-PCTA-cetuximab in cetuximab-resistant SNU-1066 HNSCC xenografted model. The cellular uptake of 64Cu/177Lu-3,6,9,15-tetraazabicyclo[9.3.1]-pentadeca-1(15),11,13-triene-3,6,9,-triacetic acid (PCTA)-cetuximab showed good correlation with western blot and flow cytometry analysis in EGFR expression level of various HNSCC cells. 177Lu-PCTA-cetuximab selectively killed cetuximab-resistant SNU-1066 cells in vitro. 64Cu-/177Lu-PCTA-cetuximab specifically accumulated in SNU-1066 tumor and those uptakes were peaked at 48 h and 7 day, respectively in biodistribution, PET and single-photon emission computed tomography/computed tomography (SPECT/CT) imaging. RIT with single dose of 177Lu-PCTA-cetuximab exhibited significant tumor regression and markedly reduced 2-[18F]fluoro-2-deoxy-D-glucose (18F-FDG) uptake, compared to other groups. Proliferation index were dramatically decreased and apoptotic index increased in RIT group. These results suggest that a diagnostic and therapeutic convergence radiopharmaceutical, 64Cu-/177Lu-PCTA-cetuximab has the potential of target selection using immuno-PET imaging and targeted therapy by RIT in EGFR expressing cetuximab-resistant HNSCC tumors.

• Publication year

  2017

• Venue

  OncoTarget

• Publication date

  2017-09-08

• Fields of study

  Medicine, Engineering

• Identifiers
  DOI 10.18632/oncotarget.20760PMID 29190900PMCID 5696166
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A comparison of overall survival for patients with T4 larynx cancer treated with surgical versus organ‐preservation approaches: A National Cancer Data Base analysis

  2017cited by this paper
• Immuno-PET Imaging and Radioimmunotherapy of 64Cu-/177Lu-Labeled Anti-EGFR Antibody in Esophageal Squamous Cell Carcinoma Model

  2016cited by this paper
• Production of 177Lu for Targeted Radionuclide Therapy: Available Options

  2015cited by this paper
• PET Imaging in Head and Neck Cancer Patients to Monitor Treatment Response: A Future Role for EGFR-Targeted Imaging

  2015cited by this paper
• Antibody positron emission tomography imaging in anticancer drug development.

  2015cited by this paper
• Positron Emission Tomography Imaging with 18F-Labeled ZHER2:2891 Affibody for Detection of HER2 Expression and Pharmacodynamic Response to HER2-Modulating Therapies

  2014cited by this paper
• 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model.

  2014cited by this paper
• Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy †

  2014cited by this paper
• RGD Peptide–Conjugated Multimodal NaGdF4:Yb3+/Er3+ Nanophosphors for Upconversion Luminescence, MR, and PET Imaging of Tumor Angiogenesis

  2013cited by this paper
• Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistance.

  2013cited by this paper
• Tumor Dosimetry Using [124I]m-iodobenzylguanidine MicroPET/CT for [131I]m-iodobenzylguanidine Treatment of Neuroblastoma in a Murine Xenograft Model

  2012cited by this paper
• Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology.

  2012cited by this paper
• Global cancer statistics

  2011cited by this paper
• Cetuximab plus radiotherapy in patients with unresectable locally advanced squamous cell carcinoma of head and neck region--a open labelled single arm phase II study.

  2011cited by this paper
• Modulation of Insulin Sensitivity and Caveolin-1 Expression by Orchidectomy in a Nonobese Type 2 Diabetes Animal Model

  2011cited by this paper
• Cetuximab-Based Immunotherapy and Radioimmunotherapy of Head and Neck Squamous Cell Carcinoma

  2010cited by this paper
• Immuno-Positron Emission Tomography: Shedding Light on Clinical Antibody Therapy

  2010cited by this paper
• Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

  2010cited by this paper
• Effect of cetuximab and fractionated irradiation on tumour micro-environment.

  2010cited by this paper
• Review of adjuvant radiochemotherapy for resected pancreatic cancer and results from Mayo Clinic for the 5th JUCTS symposium.

  2009cited by this paper
• Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.

  2009cited by this paper
• Biologically effective dose-response relationship for breast cancer treated by conservative surgery and postoperative radiotherapy.

  2009cited by this paper
• Heterogeneity of tumour response to combined radiotherapy and EGFR inhibitors: Differences between antibodies and TK inhibitors

  2009cited by this paper
• Molecular therapy in head and neck oncology

  2009cited by this paper
• Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

  2009cited by this paper
• Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum‐based therapies

  2008cited by this paper
• Platinum-based chemotherapy plus cetuximab in head and neck cancer.

  2008cited by this paper
• Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy

  2008cited by this paper
• Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.

  2007cited by this paper
• Targeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates

  2006cited by this paper
• Phase II Trial of Gefitinib 250 mg Daily in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

  2005cited by this paper
• OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine.

  2005cited by this paper
• Neck dissection in the combined‐modality therapy of patients with locoregionally advanced head and neck cancer

  2004cited by this paper
• Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.

  2004cited by this paper
• Cancer Care Ontario Practice Guidelines Initiative

  2003cited by this paper
• Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.

  2003cited by this paper
• Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review.

  2002cited by this paper
• Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer.

  2001cited by this paper
• Global cancer statistics in the year 2000.

  2001cited by this paper
• In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody.

  2000cited by this paper
• High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: a phase I trial.

  2000cited by this paper
• Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival.

  1998cited by this paper
• Epidermal growth factor receptor family and chemosensitization.

  1997cited by this paper
• High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a phase I trial.

  1997cited by this paper
• Quantitative immunohistochemical analysis of transforming growth factor‐α and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck

  1996cited by this paper
• Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model.

  1995cited by this paper
• Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer.

  1993cited by this paper
• Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma

  1993cited by this paper

• Radiotheranostic landscape: A review of clinical and preclinical development

  2025cites this paper
• Application of immunoPET imaging to enhance head and neck squamous cell carcinoma clinical management

  2025cites this paper
• Virtual tumor mapping and margin control with 3-D planning and navigation

  2024cites this paper
• Advances and residual knowledge gaps in the neck management of head and neck squamous cell carcinoma patients with advanced nodal disease undergoing definitive (chemo)radiotherapy for their primary

  2024cites this paper
• ImmunoPET: Antibody-Based PET Imaging in Solid Tumors

  2022cites this paper
• Advances in nuclear medicine-based molecular imaging in head and neck squamous cell carcinoma

  2022cites this paper
• In Vitro Tumor Cell-Binding Assay to Select High-Binding Antibody and Predict Therapy Response for Personalized 64Cu-Intraperitoneal Radioimmunotherapy against Peritoneal Dissemination of Pancreatic Cancer: A Feasibility Study

  2022cites this paper
• Dose predictions for [177Lu]Lu-DOTA-panitumumab F(ab′)2 in NRG mice with HNSCC patient-derived tumour xenografts based on [64Cu]Cu-DOTA-panitumumab F(ab′)2 – implications for a PET theranostic strategy

  2021cites this paper
• Perspectives on metals-based radioimmunotherapy (RIT): moving forward

  2021cites this paper
• Synthesis of 111In-p-SCN-Bn-DTPA-nimotuzumab and its preclinical evaluation in EGFR positive NSCLC animal model

  2021cites this paper
• Radioimmunotherapy and Targeted Radiotherapy of Squamous Cell Carcinoma of the Head and Neck

  2021cites this paper
• Prognostic Value of Urokinase-Type Plasminogen Activator Receptor PET/CT in Head and Neck Squamous Cell Carcinomas and Comparison with 18F-FDG PET/CT: A Single-Center Prospective Study

  2021cites this paper
• Characterization and Stabilization of a New 64Cu-Labeled Anti-EGFR Antibody NCAB001 for the Early Detection of Pancreatic Cancer with Positron Emission Tomography

  2021cites this paper
• Prognostic Implications of EGFR, p53, p16, Cyclin D1, and Bcl‐2 in Head and Neck Squamous Cell Carcinoma (HNSCC)

  2020cites this paper
• Positron Emission Tomography and Molecular Imaging of Head and Neck Malignancies

  2020cites this paper
• Development of a Theranostic Convergence Bioradiopharmaceutical for Immuno-PET Based Radioimmunotherapy of L1CAM in Cholangiocarcinoma Model

  2019cites this paper
• Radioimmunoimaging and Targeted Therapy

  2019cites this paper
• Integrated treatment using intraperitoneal radioimmunotherapy and positron emission tomography-guided surgery with 64Cu-labeled cetuximab to treat early- and late-phase peritoneal dissemination in human gastrointestinal cancer xenografts

  2018cites this paper
• Affibody-Based PET Imaging to Guide EGFR-Targeted Cancer Therapy in Head and Neck Squamous Cell Cancer Models

  2018cites this paper
• PET Imaging Biomarkers of Anti-EGFR Immunotherapy in Esophageal Squamous Cell Carcinoma Models

  2018cites this paper
• The Promise of Novel Biomarkers for Head and Neck Cancer from an Imaging Perspective

  2018cites this paper
• Recent Development of Nuclear Molecular Imaging in Thyroid Cancer

  2018cites this paper
• Radioimmunotherapy in Head and Neck Cancer

  2018cites this paper